Earlier this year, I noted a paper by Frank Lichtenberg that correlates life expectancy with the pace of introduction of new drugs - both of which are metrics that can be measured fairly well, and are fairly well recorded over the past few decades. So we see the expected result: one fairly general measure of the pace of progress in medicine is linked to longevity, most likely indicating that more rapid development of new medicine leads to longer lives, even when that medical progress is largely old-style drug discovery and commercial development. Here, I'll point out a few other papers along the same lines by the same author, one recent and the others from past years:

Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009

We examine the impact of pharmaceutical innovation, as measured by the vintage of prescription drugs used, on longevity, using longitudinal, country-level data on 30 developing and high-income countries during the period 2000-2009. We control for fixed country and year effects, real per capita income, the unemployment rate, mean years of schooling, the urbanization rate, real per capita health expenditure (public and private), the DPT immunization rate, HIV prevalence and tuberculosis incidence.

Life expectancy at all ages and survival rates above age 25 increased faster in countries with larger increases in drug vintage. The increase in drug vintage was the only variable that was significantly related to all of these measures of longevity growth. ... Pharmaceutical innovation is estimated to have accounted for almost three-fourths of the 1.74-year increase in life expectancy at birth in the 30 countries in our sample between 2000 and 2009, and for about one third of the 9.1-year difference in life expectancy at birth in 2009 between the top 5 countries (ranked by drug vintage in 2009) and the bottom 5 countries (ranked by the same criterion).

What to take away from this: even under the outright terrible systems of regulation that presently exist in most countries with advanced medical research communities, regulation that greatly slows progress and increases costs, the great utility of biotech research and development still filters through to this degree. Imagine how much better off we'd all be if there were no massive government agencies devoted to slowing down and blocking progress in medicine!

The older papers provide some more numbers to further flesh out the picture sketched by Lichtenberg and his colleagues. Medical progress is good - we should have more of it:

Pharmaceutical innovation and the longevity of Australians: a first look (2008)

We examine the impact of pharmaceutical innovation on the longevity of Australians during the period 1995-2003. Due to the government's Pharmaceutical Benefits Scheme, Australia has much better data on drug utilization than most other countries. We find that mean age at death increased more for diseases with larger increases in mean drug vintage. The estimates indicate that increasing the mean vintage of drugs by 5 years would increase mean age at death by almost 11 months. The estimates also indicate that using newer drugs reduced the number of years of potential life lost before the ages of 65 and 70 (but not before age 75). During the period 1995-2003, mean age at death increased by about 2.0 years, from 74.4 to 76.4. The estimates imply that, in the absence of any increase in drug vintage, mean age at death would have increased by only 0.7 years. The increase in drug vintage accounts for about 65% of the total increase in mean age at death.

Pharmaceutical Innovation, Mortality Reduction, and Economic Growth (1998)

We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and growth in lifetime per capita income. In both of the periods studied (1970-80 and 1980-91), there is a highly significant positive relationship across diseases between the increase in mean age at death (which is closely related to life expectancy) and rates of introduction of new, priority (as defined by the FDA) drugs. The estimates imply that in the absence of pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum.

The connection between wealth and longevity is strong. For a deeper historical perspective, you might look back at these posts:

• Longevity Tends to Change Economic Behavior for the Better
• Wealth and Longevity

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm